Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results ...

Freedom from university diktats is allowing campuses to catch up with the times — updating curricula and aligning education ...

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, discusses the importance ...

In this valuable study, the authors provide a simple yet elegant approach to identifying therapeutic targets that synergize to prevent therapeutic resistance in ovarian cancer using cell lines, ...

Lifezoom, a pioneer of red light therapy in the USA, is excited to expand with the new industry-leading Veyra Series, red ...

For decades, the narrative around Parkinson’s disease treatment has focused primarily on dopamine replacement. The loss of dopaminergic neurons in the substantia nigra is well recognized and drives ...

David Baker’s lab has successfully designed binders to disordered proteins, expanding therapeutic access to over 50% of the ...

Replimune Group, Inc. faces FDA setbacks with RP1, raising financial risks and dilution concerns. Click here to find out why ...

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a ...